Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

A Comprehensive Prospective Study on the 10-Year Outcome and Late Toxicity, Quality of Life of Reduced Volume Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06136962

Enrollment

500

Registered

2023-11-18

Start date

2023-12-01

Completion date

2024-12-01

Last updated

2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long term toxicity for surviving patients.This is an observational study that is being done to evaluate the long-term efficacy, learn about the toxicity and quality of life that survivors of nasopharyngeal carcinoma may have following treated with reduced volume intensity modulated radiation therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Received treatment with Reduced Volume Intensity Modulated Radiation Therapy * Age 18 or above, upper limit 65 * Ability to comply with the protocol

Exclusion criteria

* History of recurrent nasopharyngeal disease * A history of any physical, psychological or social condition which would impair with the ability of the patient to cooperate in this study * Unable to provide consent

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	10 years	Overall survival is calculated from diagnosis to death from any cause

Secondary

Measure	Time frame	Description
Failure-free survival	10 years	Failure-free survival rate is calculated from the date of diagnosis to the date of treatment failure or death from any cause, whichever is first
Distant failure-free survival	10 years	Distant failure-free survival is calculated from diagnosis to the first remote failure
Loco-regional failure-free survival	10 years	Loco-regional failure-free survival is calculated from diagnosis to the first loco-regional failure
Quality of Life Questionnaires	1year	Quality of life as measured by QLQ H&N35
Evaluation of late toxicities	1year	Clinical toxicities will be grade according to RTOG/CTCAE
Quality of Life Questionnaires QLQ-C30	1year	Quality of life as measured by QLQ-C30

Countries

China

Contacts

Primary ContactLin Shaojun, MD

linshaojun@yeah.net13860603879

Backup ContactQiaojuan Guo, MD

guoqiaojuan@163.com15080013157

Outcome results